REVIEW Indinavir is a HIV-1 protease inhibitor which inhibits the HIV viral protease enzyme, preventing cleavage of the viral gag-pol polyprotein, resulting in the formation of noninfectious, immature viral particles. Indinavir is used as a component of highly active antiretroviral therapy (HAART) to treat HIV infection and AIDS.
Boyd M. Indinavir: the forgotten HIV-protease inhibitor. Does it still have a role? Expert Opin Pharmacother (2007)8(7):957-64.
Plosker GL, Noble S. Indinavir: a review of its use in the management of HIV infection. Drugs. (1999), 58(6), 1165-203.
Pradier C, Pesce A, Carrieri P, Cottalorda J, Boyer P, Senesi C, Fuzibet JG, Dellamonica P, Cassuto JP :Effect of indinavir and higher CD4+ T-cell count on viral load response after 6 months of highly active antiretroviral therapy. Clin Ther. (1999)21(8):1313-20.
Lacy MK, Abriola KP. Indinavir: a pharmacologic and clinical review of a new HIV protease inhibitor. Conn Med. (1996), 60(12):723-7.
These chemical products are for research and development use only. They are not for diagnostic, therapeutic, cosmetic, or human and animal uses. They are not sold to individuals. Additional restrictions may apply.
New customers undergo an internal onboarding process. As part of this process, new customers may be asked for more information. CATEGORIES APIs and Bioactives > Antivirals, HIV Protease Inhibitors